Axinn Veltrop & Harkrider's Chad Landmon Speaks with Drug Industry Daily About the Drug Price Competition Act of 2009
Drug Industry DailySenator Bill Nelson (D-Fla.) has introduced the Drug Price Competition Act of 2009, a bill that could potentially impact how generic-drug makers are awarded 180-day exclusivity for their ANDA products . The bill, introduced on June 25, 2009, would allow a subsequent filer to qualify as a first applicant and trigger the 180-day exclusivity period. Chad Landmon, Chair of the FDA Practice Group at Axinn Veltrop & Harkrider LLP, spoke with Drug Industry Daily about the potential impact of the bill if it becomes law, saying, “Ultimately, I think a bill like this will certainly devalue the exclusivity period while at the same time providing opportunities for certain later filers . ”
The article, titled, “Senate Drug Price Bill May Alter 180-Day Exclusivity Awards,” was published on June 25, 2009. Click here to view a copy of the article.
From Drug Industry Daily, copyright © 2009 by Washington Business Information, Inc. (FDAnews). All rights reserved. www.fdanews.com, (888) 838-5578, +1 (703) 538-7600.